Halozyme Therapeutics Confirms It Anticipates $0 To Minimal Royalty Revenue Impact Based On Nov. 5 U.S. Centers For Medicare & Medicaid Services's Final Rule For Medicare Drug Price Negotiation Program
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the final rule for the
Halozyme says a new government drug price rule won't hurt its money much. Investors should watch if this company keeps making steady income from its partners.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.